Verrica Pharmaceuticals Inc (NASDAQ:VRCA) traded up 20% during mid-day trading on Friday after HC Wainwright raised their price target on the stock from $20.00 to $23.00. HC Wainwright currently has a buy rating on the stock. Verrica Pharmaceuticals traded as high as $11.63 and last traded at $11.62. 546,204 shares traded hands during mid-day trading, an increase of 879% from the average session volume of 55,779 shares. The stock had previously closed at $9.68.
Separately, Zacks Investment Research downgraded shares of Verrica Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, May 11th. One research analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $27.00.
In other Verrica Pharmaceuticals news, major shareholder Matt Davidson sold 4,345 shares of the business’s stock in a transaction on Tuesday, June 11th. The shares were sold at an average price of $8.49, for a total value of $36,889.05. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In the last 90 days, insiders sold 102,507 shares of company stock valued at $990,202. Insiders own 40.20% of the company’s stock.
The company’s fifty day moving average price is $8.81. The firm has a market capitalization of $298.73 million and a price-to-earnings ratio of -8.24.
Verrica Pharmaceuticals (NASDAQ:VRCA) last announced its earnings results on Tuesday, May 7th. The company reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.02). Sell-side analysts predict that Verrica Pharmaceuticals Inc will post -1.2 earnings per share for the current fiscal year.
Verrica Pharmaceuticals Company Profile (NASDAQ:VRCA)
Verrica Pharmaceuticals Inc, a clinical stage medical dermatology company, develops and commercializes dermatological treatments in the United States. The company's lead product candidate include VP-102 that is in phase III clinical trial for the treatment of molluscum contagiosum; in phase II clinical trial for the treatment of common warts; and completed phase I clinical trial for the treatment of Genital warts.
Receive News & Ratings for Verrica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verrica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.